Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in Brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The resomelagon (AP1189) Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
  • Investors
    • Capital Markets Day 2024
    • Investment highlights
    • Word from the CEO
    • Financial Reports
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectus and rights issues
      • 2025
      • 2024
      • 2023
      • 2022
      • Older
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Calendar

Upcoming events
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
  • 18
    Feb
    February 18, 2025
    Year-end report 2024
    Add to calendar
  • 10
    Apr
    April 10, 2025
    Annual Report 2024
    Add to calendar
  • 27
    May
    May 27, 2025
    Interim Report Q1 2025
    Add to calendar
  • 27
    May
    May 27, 2025
    Annual General Meeting 2025
    Add to calendar
  • 20
    Aug
    August 20, 2025
    Interim Report Q2 2025
    Add to calendar
  • 30
    Oct
    October 30, 2025
    Interim Report Q3 2025
    Add to calendar
  • 18
    Feb
    February 18, 2026
    Year-end report 2025
    Add to calendar
  • Investors
    • Capital Markets Day 2024
    • Investment highlights
    • Word from the CEO
    • Financial Reports
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectus and rights issues
      • 2025
      • 2024
      • 2023
      • 2022
      • Older
Jeppe Øvlesen
Jeppe Øvlesen
Chief Executive Officer and Board Member
+45 28 44 75 67
[email protected]
Björn Westberg
Björn Westberg
Chief Financial Officer
[email protected]

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe